RECRUITINGOBSERVATIONAL

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

About This Trial

The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Voluntarily signed the willing to sign a consent form form; 2. No restrictions on age and gender; 3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)"; 4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy. Who Should NOT Join This Trial: 1. Individuals with concurrent infections such as HIV will be excluded. 2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included. 3. Those with severe underlying diseases that affect the body's immune status will be excluded. 4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Voluntarily signed the informed consent form; 2. No restrictions on age and gender; 3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)"; 4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy. Exclusion Criteria: 1. Individuals with concurrent infections such as HIV will be excluded. 2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included. 3. Those with severe underlying diseases that affect the body's immune status will be excluded. 4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.

Treatments Being Tested

PROCEDURE

Collection of Preoperative Peripheral Blood

Prior to surgery, 30 milliliters of peripheral blood will be drawn from the subject's upper limb.

PROCEDURE

Collection of Discarded Liver Tissue During Surgery

From subjects undergoing hepatectomy or liver biopsy, discarded liver tissue will be collected during the surgical procedure.

Locations (1)

Nan

Guangzhou, Guangdong, China